Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeted ablation of the phospholamban gene is associated with a marked decrease in sensitivity in aortic smooth

J Lalli1, J M Harrer, W Luo

  • 1University of Cincinnati, College of Medicine, Department of Molecular and Cellular Physiology, OH 45267-0576, USA.

Circulation Research
|April 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

AB-1002 gene therapy expressing active protein phosphatase inhibitor-1 in heart failure: Rationale and study design of the GenePHIT trial.

European journal of heart failure·2026
Same author

Steroids originating from bacterial bile acid degradation affect Caenorhabditis elegans and indicate potential risks for the fauna of manured soils.

Scientific reports·2019
Same author

Evaluation of the Microbial Quality of Raw Milk <sup>1</sup>.

Journal of food protection·2019
Same author

Prevalence and cardiac phenotype of patients with a phospholamban mutation.

Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·2018
Same author

Phospholamban ablation rescues the enhanced propensity to arrhythmias of mice with CaMKII-constitutive phosphorylation of RyR2 at site S2814.

The Journal of physiology·2015
Same author

Altered regional cardiac wall mechanics are associated with differential cardiomyocyte calcium handling due to nebulette mutations in preclinical inherited dilated cardiomyopathy.

Journal of molecular and cellular cardiology·2013

Phospholamban (PLB) regulates vascular smooth muscle contractility by modulating sarcoplasmic reticulum Ca(2+)-ATPase activity. Mice lacking PLB showed altered aortic contractility, with differences abolished by inhibiting the Ca(2+)-ATPase.

Area of Science:

  • Cardiovascular Physiology
  • Muscle Biology
  • Molecular Pharmacology

Background:

  • Phospholamban (PLB) is known to regulate sarcoplasmic reticulum (SR) Ca(2+)-ATPase in cardiac muscle.
  • Its role in vascular smooth muscle (VSM) contractility remains less understood.

Purpose of the Study:

  • To investigate the in vivo role of phospholamban (PLB) in regulating vascular smooth muscle contractility.
  • To elucidate the specific mechanisms by which PLB influences VSM function.

Main Methods:

  • Generation of phospholamban-deficient (PLB-) mice using targeted gene deletion.
  • Assessment of aortic contractility using phenylephrine and KCl stimulation.
  • Pharmacological inhibition of SR Ca(2+)-ATPase using cyclopiazonic acid (CPA).

Related Experiment Videos

Main Results:

  • PLB- mice exhibited altered aortic contractility, with faster force development and reduced sensitivity to stimuli.
  • No significant differences in maximum force or time course for KCl contractures were observed.
  • Inhibition of SR Ca(2+)-ATPase with CPA abolished the contractility differences between PLB- and wild-type aortas.

Conclusions:

  • Phospholamban (PLB) acts as a regulator of the SR Ca(2+)-ATPase in mouse aorta.
  • PLB plays a significant role in both receptor-mediated and KCl-induced vascular smooth muscle contractility.
  • These findings highlight PLB as a key modulator of vascular tone.